Table 1.

Patients' characteristics

Patient no.Primary tumorCumulated dose of erlotinib (150 mg × no. days)Cutaneous toxicityFollow-up (mo)Events/clinical status
1Oral cavity1,950236DF
2Oral cavity3,000248DF
3Oral cavity3,750148DF
4Oral cavity2,700218DRD
5Hypopharynx2,85027DRD
6Oral cavity2,700048DF
7Oropharynx3,300235DRD
8Oral cavity3,450248DF
9Larynx4,050038DF
10Oropharynx3,600137DuRD
11Oral cavity3,000136DF
12Oral cavity1,650312LR
13Oropharynx3,450134DF
14Larynx750318DF
15Larynx3,000114DRD
16Larynx3,600116DuRD
17Oral cavity3,900127DF
18Oral cavity4,95016DRD
Mean3,091.7Mean29.2
SD928.9SD14.3
Max4,950.0Max48.0
Min750.0Min6.0

NOTE: The tumor localization, cumulated dose of erlotinib, toxicity, and follow-up are detailed for 18 patients with nonmetastatic HNSCC who received neoadjuvant treatment with erlotinib between panendoscopy and surgical treatment.

Abbreviations: DF, disease-free; DRD, death related to the disease; DuRD, death unrelated to the disease; LR, local relapse.